1 The EIC Accelerator Project

The European Innovation Council (EIC) Accelerator program is designed to support small and medium-sized enterprises (SMEs) and startups in scaling their innovative technologies and solutions. The program primarily targets deep-tech companies that exhibit high growth potential and address pressing societal challenges. It offers a unique blend of funding options, including grants and equity investments, specifically tailored to foster innovation and technological advancement within the European ecosystem.

Funding Structure of the EIC Accelerator

The EIC Accelerator provides substantial financial support, which consists of two main components:

Purpose and Impact of the EIC Accelerator

The EIC Accelerator serves a critical role in the European DeepTech and startup ecosystem by providing financial resources and strategic support to high-impact innovations. The program aims to bridge the funding gap often encountered by innovative companies, particularly in sectors that require substantial initial investment and exhibit longer development cycles. By facilitating access to capital, the EIC Accelerator empowers startups to scale their operations, accelerate time-to-market, and enhance their competitiveness on a global scale.

Moreover, the EIC Accelerator encourages collaboration between startups and private investors, thereby fostering a vibrant innovation ecosystem. By attracting private sector funding alongside its own investments, the program enhances the overall investment landscape for deep-tech initiatives in Europe.

Case Study: ADVANCED MARKER DISCOVERY SL and the ColoDix Project

Company Overview: ADVANCED MARKER DISCOVERY SL, based in Spain, is a pioneering company focused on developing advanced diagnostic tools for early cancer detection. The company leverages cutting-edge biomarker technology and artificial intelligence (AI) to revolutionize the screening and diagnosis of colorectal cancer.

Project Overview: The ColoDix project aims to facilitate the early detection of colorectal cancer through blood tests that utilize the latest generation of biomarkers combined with sophisticated AI tools. The project was submitted to the EIC Accelerator on October 6, 2021, and successfully advanced through the selection process, culminating in a Step 3 interview where it secured funding.

Technology Background of ColoDix

The ColoDix project is centered around the innovative use of biomarkers—biological molecules that indicate the presence of a disease. In the context of colorectal cancer, these biomarkers are critical for enabling earlier and less invasive screening methods compared to traditional diagnostic procedures such as colonoscopy.

The integration of AI tools plays a significant role in enhancing the accuracy and efficiency of the diagnostic process. Machine learning algorithms can analyze vast datasets to identify patterns and correlations that may not be apparent through conventional analysis. This capability allows for improved sensitivity and specificity in detecting colorectal cancer at its earliest stages.

The technology underlying ColoDix represents a confluence of advancements in molecular biology, data analytics, and clinical diagnostics. By focusing on non-invasive blood tests, the project addresses a significant barrier to early cancer detection—patient reluctance associated with more invasive procedures. The potential for increased screening compliance could lead to earlier interventions, ultimately improving patient outcomes and reducing healthcare costs associated with late-stage cancer treatment.

Through the EIC Accelerator funding, ADVANCED MARKER DISCOVERY SL is poised to make significant strides in the field of oncology, contributing to the broader goal of enhancing public health through innovative technology. The ColoDix project exemplifies the transformative potential of deep-tech innovations in addressing critical healthcare challenges.

2 The Funding Rounds

Advanced Marker Discovery SL (Amadix), a Spanish biotechnology company specializing in early cancer detection through innovative non-invasive diagnostic tests, has shown a funding trajectory primarily supported by venture capital and public grants, including significant EIC Accelerator funding.

Financing Raised and Funding Rounds

• Amadix has historically raised funds supported by several key Spanish venture capital investors specialized in biotechnology and medical devices. Notable VC funds involved include Cross Road Biotech, Inveready, Clave Mayor, ADE Capital Sodical, Alentia, CRB Inverbio, and INNVIERTE (CDTI). These investors have provided both financial backing and business development support since the company's early stages.
• The company sought to raise up to €5 million around 2016–2018 to support its product development pipeline toward commercializing cancer diagnostic tests in Europe and the US. While detailed rounds beyond this are not publicly disclosed explicitly as separate series rounds (e.g., Series A or B), Amadix’s financing approach combines private equity from VCs with public soft funding.
• Amadix benefits from multiple public grants co-financed by European Union programs such as FEDER funds via Spain’s Enterprise Competitiveness Institute (ICE) for projects related to big data algorithms for cancer detection ("BigDatCancer") and other AI-driven platforms. Additionally, it received Next Generation EU/PRTR funding for disruptive colorectal cancer detection technologies under project CPP2021/008536.
• The company also secured grant support from the Spanish Ministry of Industry under AEI programs aimed at enhancing competitiveness through digital AI platforms in clinical data management.

Timing and Amount of Funding Rounds

• Specific private financing round dates are not fully detailed publicly; however:
• Prior to 2018: Early-stage venture capital investments were secured.
• October 2021: Advanced Marker Discovery won EIC Accelerator funding following submission on October 6th, 2021. This program typically provides blended finance combining grants plus equity investments designed to scale promising deep-tech ventures like Amadix.
• The average ticket size for EIC Accelerator beneficiaries is approximately €6 million per company with a typical breakdown of about €2.46 million grant plus €3.7 million equity on average across recipients; while exact figures specific to Amadix's award are undisclosed publicly this gives an indicative scale of investment available post their successful Step 3 interview win in late 2021.

Investor Information

• Venture capital investors known by name include Cross Road Biotech, Inveready Ventures Capital Fund management firm specialized in technology sectors including biotech; Clave Mayor; ADE Capital Sodical; Alentia Ventures; CRB Inverbio; INNVIERTE (CDTI) – a government-backed initiative supporting technology startups.
• Financial institutions such as Banco Sabadell, CaixaBank, Cajamar have also backed Amadix financially or via credit facilities supporting operations alongside investor rounds.

Company Valuations & Exit Events

• There is no publicly available information indicating any exit events such as mergers or acquisitions involving Advanced Marker Discovery SL up until April 2025.
• Valuation specifics have not been disclosed openly but can be inferred that the valuation would align with typical biotech startup levels when raising multi-million euro rounds focusing on molecular diagnostics validated through EU innovation grants combined with private VC interest.

Summary Table of Funding Highlights

Year	Funding Type	Approximate Amount	Investors / Source	Notes
Pre-2018	Venture Capital	Up to ~€5M	Cross Road Biotech et al., various VCs	Early-stage fundraising focused on product pipeline
Various	Public Grants	Several hundred thousand euros	ICE/FEDER/EU NextGenEU/Spanish Ministry	Multiple R&D projects linked to AI & cancer detection
Oct 2021	EIC Accelerator	Estimated ~€6M blended finance	European Innovation Council	Blended grant+equity post Step3 success

(*Exact amounts per project/grant confidential/not fully published)

---

Overall, since submitting their Step 2 proposal on October 6th, 2021 and winning at Step 3 interview stage for the EIC Accelerator program funded by the EU Commission framework Horizon Europe / Next Generation EU funds alongside their established VC backing from Spain-based specialized investors like Inveready and others — Advanced Marker Discovery SL has maintained robust financial support combining private venture capital with substantial public innovation grants dedicated toward developing non-invasive early cancer diagnostics based on liquid biopsy technologies that hold FDA breakthrough device designation potential.

Sources: - amadix.com acknowledgments

• Amadix Executive Summary PDF
• Gust profile AMADIX
• Investors page - amadix.com
• EIC Accelerator latest results analysis

3 The Press Releases

Advanced Marker Discovery SL (Amadix) Overview

Advanced Marker Discovery SL, commonly known as Amadix, is a Spanish biotechnology company based in Valladolid. Founded in 2010, Amadix specializes in developing innovative diagnostic tests for early cancer detection using cutting-edge biomarkers. These tests are designed to be non-invasive, using samples from blood, urine, or saliva to diagnose various types of cancer, thereby reducing the complications associated with invasive procedures.

Funding and Projects

Amadix has received significant funding for several projects:

• BigDatCancer: This project involves the development of an algorithm for early detection of colon cancer using big data and artificial intelligence tools.
• ALMATIC: Focuses on creating algorithms for a data analysis platform in maintenance, predictive quality, and health problems.
• TEDCRC (Disruptive Technologies for the Early Detection of Colorectal Cancer): Funded by the Ministry of Industry, Trade and Tourism and the European Union's Next Generation EU program, this project aims at disrupting early detection methods for colorectal cancer.
• Digital Platform for Managing Clinical Data: A grant was awarded for developing a digital platform to manage clinical data analyzed with AI and big data for early cancer detection.
• dataLung: This project involves developing algorithms for early detection of lung cancer and indeterminate lung nodule malignancy using digital markers.

Technology and Innovations

Amadix is at the forefront of leveraging AI and big data in biomarker discovery. The integration of AI in cancer diagnostics enhances precision by identifying complex patterns and improving sensitivity and specificity in testing. This approach allows for earlier detection and more personalized treatment strategies.

Partnerships and Updates

There is no specific information available on recent partnerships or team updates directly from Amadix's website or press releases. However, the company's involvement in various funded projects indicates active collaboration with European and Spanish institutions.

Press Releases and Blog Posts

Amadix does not appear to have a dedicated section for press releases or blog posts on its website. However, their project acknowledgments section provides insights into their ongoing projects and funding sources.

---

Sources:

• Advanced Marker Discovery SL
• Lung Cancer Diagnostic Tests - Medical Devices Pipeline
• CD58 could be a leukemic marker in patients with relapsed B-ALL
• Announcing Advanced Markers
• Google Health Research Publications
• AI-driven biomarker discovery
• Advances in Biomarker Discovery and Analysis
• Science Journals Editorial Policies
• AMADIX (ADVANCED MARKER DISCOVERY, SL)
• Advanced Markers | Maps JavaScript API

4 The Technology Advancements

Advanced Marker Discovery S.L. (Amadix): Current Capabilities and Advancements

Advanced Marker Discovery S.L., known as Amadix, is a Spanish company specializing in the development of innovative diagnostic tests for cancer. Their primary focus is on early cancer detection using state-of-the-art liquid biopsy techniques. Since receiving the EIC Accelerator funding in October 2021, Amadix has continued to advance its capabilities in cancer diagnostics.

Current Capabilities

Amadix is renowned for its work in developing algorithms and platforms for early cancer detection. They have been involved in several projects, including "BigDatCancer" and "ALMATIC," which focus on using big data and artificial intelligence for predictive maintenance and health-related issues. Additionally, they have developed the PreveCol™ test, a blood-based diagnostic tool for colorectal cancer (CRC) that demonstrates high sensitivity and specificity.

Advancements Since EIC Accelerator Funding

Since receiving EIC funding, Amadix has made significant strides in advancing its technology. The company has been involved in the development and validation of novel diagnostic tests, particularly for colorectal cancer. The PreveCol™ test, which combines molecular biomarkers and clinical features, has shown promising results in early-stage CRC detection, with a high Area Under the ROC curve (AUC) of 92%.

New Features and Technology Demonstrations

Amadix has been actively engaged in clinical trials and validation studies. For example, they are sponsoring a clinical trial for the development and validation of a blood test for early diagnosis of colorectal cancer in Spain. This indicates their commitment to demonstrating their technology in real-world settings.

New Patents, Scientific Studies, or Clinical Trials

While specific details about new patents or studies directly linked to the EIC funding are not readily available, Amadix's ongoing projects, such as the PreveCol™ validation, suggest continued innovation in cancer diagnostics. Their work on AI-driven biomarker discovery aligns with broader trends in precision medicine, where AI is increasingly used to enhance diagnostic accuracy.

Conclusion

Amadix continues to be at the forefront of cancer diagnostics, leveraging advanced technologies like AI and liquid biopsies. Their focus on early detection and innovative diagnostic tools positions them well within the oncology sector.

---

Used Sources:

• Advanced Marker Discovery, S.L. - Projects
• Amadix - Investors
• ColoDix Project Details
• Journal of Clinical Oncology - PreveCol Study
• Clinical Trials - Development and Validation of a Blood Test for Early Diagnosis of Colorectal Cancer

5 The Partnerships and Customers

Advanced Marker Discovery, S.L. (Amadix) - An Overview Since EIC Accelerator Funding

Advanced Marker Discovery, S.L., commonly known as Amadix, is a Spanish molecular diagnostics company specializing in innovative diagnostic tests for cancer. Following their success in the EIC Accelerator funding in October 2021, Amadix has continued to advance its mission of developing cutting-edge diagnostic solutions.

Partnerships and Customers

Amadix has not publicly disclosed specific new partners or customers. However, its strategic collaborations are often tied to its research projects and technological advancements. Notably, Amadix acquired Transbiomed in 2012, gaining access to intellectual property and resources from Vall d'Hebron University Hospital, a leading Spanish oncology center.

New Relationships and Market Positioning

Amadix's focus on early cancer detection using AI-driven biomarkers positions it as a pioneer in precision medicine. New relationships, while not explicitly listed, likely involve collaborations with research institutions or technology companies to further enhance its diagnostic capabilities. These partnerships would be crucial for Amadix to scale its operations and technologies, potentially expanding its reach in the global market for cancer diagnostics.

Purpose and Impact of Relationships

The purpose of new relationships would likely center around advancing Amadix's technology through collaborative research and development, accessing new markets, and enhancing its product portfolio. By leveraging AI in biomarker discovery, Amadix aims to improve the accuracy and efficiency of cancer diagnostics, which could significantly enhance patient outcomes and survival rates.

Technology Advancements and Scaling

The integration of AI and machine learning into biomarker research is a key area of growth for Amadix. These technologies enable the company to identify complex biomarker signatures, leading to more precise cancer screening and personalized therapies. As Amadix scales, its partnerships will be essential in accessing new technologies, expanding clinical trials, and commercializing its diagnostic tests globally.

Conclusion

Amadix's innovative approach to cancer diagnostics, combined with strategic partnerships and technological advancements, positions it strongly in the global healthcare market. Continued investment in AI-driven biomarkers and collaborations with leading research institutions will be vital for its growth and success.

Source URLs:

• Advanced Marker Discovery, S.L.
• Amadix Executive Summary
• EIC Accelerator Data Hub
• EuroQuity Profile
• Colorectal Cancer Screening Tests Pipeline
• AI-Driven Biomarker Discovery

6 The Hiring and Company Growth

Advanced Marker Discovery SL (Amadix), a Spanish biotechnology company specializing in innovative diagnostic tests for early cancer detection, had an estimated team size of about 10 employees as of recent data from around 2024-2025.

Regarding hiring and team growth since receiving the EIC Accelerator funding in October 2021:

• There is no publicly available detailed information on significant changes in headcount or precise current team size beyond the stated approximate number of 10 employees.
• No explicit data are found indicating recent or ongoing hiring efforts, nor specific key positions recently filled within Amadix.
• There is also no public record of major management or founding team changes since their EIC Accelerator award.

The company has been actively involved in R&D projects funded by various European grants focusing on AI-based algorithms and molecular markers for early cancer detection, such as colon and lung cancer projects. These innovations suggest a focus on enhancing their technological capabilities that likely require skilled personnel to scale diagnostics development and commercialization efforts.

Given Amadix's specialization in biomarker-based diagnostics and their engagement with cutting-edge AI tools for oncology applications, any future hires would probably focus on roles such as bioinformatics specialists, molecular biologists, clinical research experts, software/data scientists focused on AI algorithm development, and regulatory affairs professionals. Expanding these areas would help them accelerate product development pipelines and market readiness.

In summary: | Aspect | Status/Info | |-------------------------------------|-----------------------------------| | Current known headcount | ~10 employees | | Team growth since EIC funding | Not explicitly documented | | Current hiring status | Unknown / not publicly indicated | | Recent key hires | Not disclosed | | Major management/founding changes | None publicly known | | Implication of new team members | Likely to support scaling R&D & commercialization focused on AI-driven biomarker diagnostics |

Without further direct disclosures from Amadix or updated corporate filings providing staffing plans or recruitment announcements post-EIC funding win (Oct 2021), this remains the most accurate assessment based on available information.

Sources

• Amadix Company Profile - Gust
• Amadix Acknowledgments & Projects
• Investor Information - Amadix

7 The Media Features and Publications

Advanced Marker Discovery SL: Media Features, Publications, and Events

Advanced Marker Discovery SL, an EIC Accelerator winner from Spain, is a pioneering company in the field of early cancer detection using advanced technologies like Big Data and Artificial Intelligence. Since receiving the EIC funding in October 2021, the company has been actively involved in various projects and initiatives.

Media Features and Publications

While specific media features or publications directly naming Advanced Marker Discovery SL are not readily available, the company's projects and grants have been recognized through various funding announcements. For instance, Advanced Marker Discovery has received funding for several significant projects, including the "Disruptive and high accuracy test for early colorectal cancer detection" under the EIT Health initiative. Additionally, they have received grants from the European Union’s Horizon 2020 research and innovation program for projects like "AMX Data," focusing on identifying risk factors for colorectal cancer using Big Data tools and AI.

Podcasts and Interviews

There is no available information on podcasts or interviews performed by the team of Advanced Marker Discovery SL. Their focus appears to be more on technological innovation and less on public media appearances.

Conference and Fair Visits, Presentations, or Participations

Advanced Marker Discovery SL has likely participated in events related to healthcare technology and innovation, although specific details about their participation in conferences or fairs are not readily available. Given their involvement with European funding bodies like EIT Health and the Horizon 2020 program, they may have participated in relevant scientific conferences or innovation fairs within Europe.

Involvement in Events

The company's involvement in events is primarily through the projects they undertake with the support of various European and Spanish funding bodies. These events could include scientific conferences, technology fairs, or workshops focused on cancer detection and AI in healthcare.

Sources:

• Projects - Amadix
• Disruptive and high accuracy test for early colorectal cancer ...
• Legal Notice - Amadix
• Advanced Marker Discovery, S.L. (AMADIX)'s US Patent application